Advertisement
NMRA vs SLBT
Which Stock Would AI Choose? Neumora Therapeutics (NMRA) vs. SL Science Holding (SLBT) Stock Comparison
Key Takeaways
- NMRA is a clinical-stage biopharmaceutical company with multiple late-stage catalysts, while SLBT is a newly listed, micro-cap bioscience and skincare company that has experienced steep post-listing price declines.
- Neumora ended its most recent quarter with roughly $147 million in cash, providing a runway into 2027, whereas SL Science Holding operates with a much smaller revenue base and negative profitability.
- SLBT shares have fallen sharply since their June 2026 Nasdaq debut, while NMRA has maintained a more established trading history and broader institutional and analyst coverage.
- Tickeron AI Verdict: NMRA currently shows the more favorable relative positioning based on trend consistency, pipeline catalysts, and balance-sheet stability.
- For additional detail, review the latest NMRA Major News and NMRA Today's Price Move pages, as well as SLBT Major News and SLBT Today's Price Move.
- To see which strategies the AI platform is prioritizing across the broader market, explore Trending AI Robots.
Introduction
Investors evaluating emerging healthcare names often weigh clinical-stage drug developers against earlier-stage bioscience businesses, and this stock comparison between NMRA and SLBT captures exactly that contrast. Neumora Therapeutics is a neuroscience-focused biopharmaceutical company with a defined pipeline and multiple data readouts ahead, while SL Science Holding is a Taiwan-based company combining skincare products with early-stage cell-therapy research that only recently became publicly traded through a merger. Their relative performance and market positioning differ sharply, making this comparison relevant for traders assessing volatility, momentum, and long-term investors evaluating fundamentals and catalysts.
NMRA Overview and Recent Performance
Neumora Therapeutics is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, developing therapies for neuropsychiatric and metabolic conditions. Its pipeline includes navacaprant for major depressive disorder (MDD), NMRA-511 for agitation associated with Alzheimer's disease, NMRA-898 for schizophrenia, and NMRA-215 for obesity. In recent weeks, the company has emphasized full enrollment of its KOASTAL-2 and -3 studies and reiterated plans for a joint data readout, alongside additional clinical updates expected later in the year. Sentiment has been shaped by earlier mixed trial results, but the company's cash position of approximately $147 million supports operations into 2027. Analyst coverage has included upgrades based on pipeline optionality, reflecting a cautiously constructive view of the company's risk-reward profile.
SLBT Overview and Recent Performance
SL Science Holding, formerly SL Bio Co., Ltd., is a Taipei-based company operating across skincare, scalp-care products, and early-stage biomedical research, including armed T-cell and gamma delta T-cell technologies. The company became publicly traded on Nasdaq in mid-2026 after completing a business combination with a special purpose acquisition company (SPAC). Its shares have exhibited pronounced volatility since listing, with the stock declining significantly over recent months and trading well below its early listing price. With a relatively small revenue base and negative net income, SLBT's recent behavior reflects post-merger repricing, thin trading liquidity, and investor caution around its early-stage, capital-intensive development programs rather than any single reported catalyst.
Trending AI Robots
Tickeron operates a broad ecosystem of AI-powered trading bots that analyze thousands of tickers across varied strategies, timeframes, and risk profiles. Because no single bot suits every market condition, Tickeron curates a dedicated Trending AI Robots section highlighting only the strategies currently performing best and best matched to prevailing market dynamics. These bots differ in trading style, holding period, performance statistics, and the specific sets of tickers they monitor, giving traders a range of approaches to evaluate. Whether you follow momentum, trend-following, or volatility-based signals, reviewing the curated list can help identify automated strategies aligned with today's conditions. Explore the Trending AI Robots page to see which models are currently standing out.
Head-to-Head Comparison
The two companies sit at opposite ends of the healthcare spectrum. NMRA is a pure-play drug developer whose value hinges on binary clinical outcomes, with a comparatively deep pipeline and defined catalysts spread across neuroscience and obesity. SLBT blends a commercial skincare business with preclinical cell-therapy research, giving it a diversified but much earlier-stage and less predictable revenue profile. From a momentum standpoint, NMRA has shown more orderly trading patterns with active analyst coverage, whereas SLBT has experienced steep drawdowns and elevated volatility typical of newly de-SPACed micro-caps. Risk profiles differ accordingly: NMRA faces clinical and regulatory binary risk, while SLBT faces execution, liquidity, and commercialization uncertainty alongside a smaller cash base.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst density, balance-sheet stability, and relative market positioning, Tickeron's AI would likely favor NMRA over SLBT in the current environment. Neumora's combination of a defined clinical pipeline, a cash runway extending into 2027, and more established institutional coverage offers a comparatively more stable foundation, while SLBT's steep post-listing decline and limited operating scale present greater uncertainty. This assessment is probabilistic rather than definitive, reflecting the likelihood of more favorable near-term positioning rather than a guaranteed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NMRA is a Hold and SLBT is a StrongBuy.
NMRA in +55.47% Uptrend, advancing for three consecutive days on November 03, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NMRA as a result. In 43 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 15 of 20 cases over the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 63 of 83 cases where NMRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 35 cases where NMRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NMRA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.124) is normal, around the industry mean (3.498). P/E Ratio (-0.409) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SLBT's RSI Indicator remains in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLBT advanced for three days, in 19 of 32 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
SLBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SLBT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 23 similar instances when the indicator turned negative. In 8 of the 23 cases the stock turned lower in the days that followed. This puts the odds of success at 35%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SLBT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. SLBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SLBT's P/B Ratio (476.190) is very high in comparison to the industry average of (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| NMRA | SLBT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 86% | N/A |
| MACD ODDS (%) | 4 days ago 75% | 2 days ago 35% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 10 days ago 87% | 4 days ago 59% |
| Declines ODDS (%) | 3 days ago 87% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NMRA’s FA Score shows that 1 FA rating(s) are green while SLBT’s FA Score has 0 green FA rating(s).
- NMRA’s FA Score: 1 green, 4 red.
- SLBT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NMRA’s TA Score shows that 5 TA indicator(s) are bullish while SLBT’s TA Score has 4 bullish TA indicator(s).
- NMRA’s TA Score: 5 bullish, 3 bearish.
- SLBT’s TA Score: 4 bullish, 3 bearish.
Price Growth
NMRA (@Biotechnology) experienced а -16.43% price change this week, while SLBT (@Biotechnology) price change was -34.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
NMRA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NMRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with SLBT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then SLBT could also see price increases.
| Ticker / NAME | Correlation To NMRA | 1D Price Change % | ||
|---|---|---|---|---|
| NMRA | 100% | +1.37% | ||
| SLBT - NMRA | 44% Loosely correlated | -19.64% | ||
| CNTX - NMRA | 40% Loosely correlated | +15.56% | ||
| SNDX - NMRA | 35% Loosely correlated | +1.05% | ||
| CRVO - NMRA | 33% Loosely correlated | +29.20% | ||
| ADCT - NMRA | 33% Poorly correlated | +5.96% | ||
More | ||||
SLBT and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLBT has been loosely correlated with NMRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SLBT jumps, then NMRA could also see price increases.
| Ticker / NAME | Correlation To SLBT | 1D Price Change % | ||
|---|---|---|---|---|
| SLBT | 100% | -19.64% | ||
| NMRA - SLBT | 45% Loosely correlated | +1.37% | ||
| CRVO - SLBT | 39% Loosely correlated | +29.20% | ||
| AZR - SLBT | 22% Poorly correlated | -2.39% | ||
| HIND - SLBT | 5% Poorly correlated | +0.65% | ||
| KYNB - SLBT | 3% Poorly correlated | +3.08% | ||
More | ||||